Ultrafast shape recognition: Method and applications

Future Medicinal Chemistry

Volumn 3, Issue 1, 2011, Pages 65-78

  Ballester, Pedro J ^a  

^a EUROPEAN BIOINFORMATICS INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARYLAMINE N ACETYLTRANSFERASE INHIBITOR; ENZYME INHIBITOR; FACIPAIN 2 INHIBITOR; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ACCURACY; AREA UNDER THE CURVE; BIOINFORMATICS; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; DRUG SCREENING; IC 50; METHODOLOGY; MOLECULAR RECOGNITION; PRIORITY JOURNAL; REVIEW; ULTRAFAST SHAPE RECOGNITION; VELOCITY;

ANIMALS; COMPUTER SIMULATION; DRUG DESIGN; HUMANS; MODELS, MOLECULAR; TIME FACTORS;

EID: 78650643212     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.10.280     Document Type: Review

References (41)

1. Drewry DH, Macarron R. Enhancements of screening collections to address areas of unmet medical need: an industry perspective. Curr. Opin. Chem. Biol. 14, 289-298 (2010).
2. Peakman T, Franks S, White C, Beggs M. Delivering the power of discovery in large pharmaceutical organizations. Drug Discov. Today 8, 203-211 (2003).
3. Schneider G. Virtual screening: an endless staircase? Nat. Rev. Drug Discov. 9, 273-276(2010). n Perspective on the current role of virtual screening and its expected future development.
4. Zauhar RJ, Moyna G, Tian L, Li Z, Welsh WJ. Shape signatures, a new approach to computer-aided ligand- and receptor-based drug design. J. Med. Chem. 46, 5674-5690 (2003).
5. Kortagere S, Krasowski MD, Ekins S. The importance of discerning shape in molecular pharmacology. Trends Pharmacol. Sci. 30, 138-147 (2009).
6. Ebalunode JO, Zheng W. Molecular shape technologies in drug discovery: methods and applications. Curr. Top. Med. Chem. 10, 669-679 (2010). n Comprehensive review of molecular shape similarity techniques applied to drug discovery.
7. Ballester PJ, Richards WG. Ultrafast shape recognition to search compound databases for similar molecular shapes. J. Comput. Chem. 28, 1711-1723 (2007).
8. Ballester PJ, Richards WG. Ultrafast shape recognition for similarity search in molecular databases. Proc. R. Soc. A 463, 1307-1321 (2007).
9. Ballester PJ, Westwood I, Laurieri N, Sim E, Richards WG. Prospective virtual screening with ultrafast shape recognition: the identification of novel inhibitors of arylamine N-acetyltransferases. J. R. Soc. Interface 7(43), 335-342 (2010). nn First prospective application of USR, which led to an outstanding proportion of novel inhibitors with diverse chemical structure.
10. Grant JA, Pickup BT. A Gaussian description of molecular shape. J. Phys. Chem. 99, 3503-3510 (1995). The introduction of the ROCS method.
11. Cannon EO, Nigsch F, Mitchell JBO. A novel hybrid ultrafast shape descriptor method for use in virtual screening. Chem. Cent. J. 2(3) (2008).
12. Nicholls A, McGaughey GB, Sheridan RP et al. Molecular shape and medicinal chemistry: a perspective. J. Med. Chem. 53, 3862-3886 (2010).
13. Armstrong MS, Morris GM, Finn PW, Sharma R, Richards WG. Molecular similarity including chirality. J. Mol. Graph. Model. 28, 368-370 (2009).
14. Zhou T, Lafleur K, Caflisch A. Complementing ultrafast shape recognition with an optical isomerism descriptor. J. Mol. Graph. Model.29(3), 443-449 (2010).
15. Lafleur K, Huang D, Zhou T, Caflisch A, Nevado C. Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor b4 (EphB4). J. Med. Chem. 52, 6433-6446 (2009).
16. 2O)nn ≤ 8. J. Phys. Chem. A 112, 6257-6261(2008).
17. Soh H, Ong Y-S, Nguyen QC. Discovering unique, low-energy pure water isomers: memetic exploration, optimization, and landscape analysis. IEEE Trans. Evol. Computat. 14(3), 419-437 (2010).
18. Schreyer A, Blundell TL. CREDO: a protein-ligand interaction database for drug discovery. Chem. Biol. Drug Des. 73, 157-167 (2009).
19. Lee S, Blundell TL. BIPA: a database for protein-nucleic acid interaction in 3D structures. Bioinformatics 25, 1559-1560 (2009).
20. Guha R, Gilbert K, Fox G, Pierce M, Wild D, Yuan H. Advances in cheminformatics methodologies and infrastructure to support the data mining of large, heterogeneous chemical datasets. Curr. Comput. Aided Drug Des. 6, 50-67 (2010). n Pilot study demonstrating the suitability of USR to allow interactive 3D shape similarity searches in PubChem.
21. Zhu Q, Lajiness MS, Ding Y, Wild DJ. WENDI: a tool for finding non-obvious relationships between compounds and biological properties, genes, diseases and scholarly publications. J. Cheminform. 2(6) (2010).
22. Ballester PJ, Finn PW, Richards WG. Ultrafast shape recognition: evaluating a new ligandbased virtual screening technology. J. Mol. Graph. Model. 27, 836-845 (2009).
23. Huang N, Shoichet B, Irwin J. Benchmarking sets for molecular docking. J. Med. Chem. 49, 6789-6801 (2006).
24. Truchon J, Bayly CI. Evaluating virtual screening methods: good and bad metrics for the early recognition problem. J. Chem. Inf. Model. 47, 488-508 (2007).
25. Kirchmair J, Distinto S, Markt P et al. How to optimize shape-based virtual screening:choosing the right query and including chemical information. J. Chem. Inf. Model. 49, 678-692(2009). n Study demonstrating the importance of using several active molecules as templates to improve ligand-based virtual screeningperformance.
26. Armstrong MS, Morris GM, Finn PW et al. ElectroShape: fast molecular similarity calculations incorporating shape, chirality and electrostatics. J. Comput. Aided Mol. Des. 24(9), 789-801 (2010).
27. Parker CN. McMaster University data-mining and docking competition: computational models on the catwalk. J. Biomol. Screen.10, 647-648 (2005).
28. Lang PT, Kuntz ID, Maggiora GM, Bajorath J. Evaluating the high-throughput screening computations. J. Biomol. Screen. 10, 649-652 (2005).
29. Irwin J. Community benchmarks for virtual screening. J. Comput. Aided Mol. Des. 22, 193-199 (2008).
30. Rodrigues-Lima F, Dairou J, Busi F, Dupret J. Human arylamine N-acetyltransferase 1: a drug-metabolizing enzyme and a drug target? Curr. Drug Targets 11, 759-766 (2010).
31. Irwin JJ, Shoichet BK. ZINC - a free database of commercially available compounds for virtual screening. J. Chem. Inf. Model. 45,177-182 (2005). nn Presentation of the ZINC database, an extremely useful resource for prospective virtual screening.
32. Li H, Huang J, Chen L et al. Identification of novel falcipain-2 inhibitors as potential antimalarial agents through structure-based virtual screening. J. Med. Chem. 52, 4936-4940 (2009).
33. Ballester PJ, Mitchell JBO. A machine learning approach to predicting protein-ligand binding affinity with applications to molecular docking. Bioinformatics 26, 1169-1175 (2010).
34. Kaiser J. Industrial-style screening meets cademic biology. Science 321, 764-766 (2008).
35. Oprea TI, Bologa CG, Boyer S et al. A crowdsourcing evaluation of the NIH chemical probes. Nat. Chem. Biol. 5, 441-447 (2009).
36. Vasudevan SR, Churchill GC. Mining free compound databases to identify candidates selected by virtual screening. Expert Opin. Drug Discov. 4, 901-906 (2009). n Perspective on how virtual screening is ready to power up academic hit identification.
37. Parker CN, Bajorath J. Towards unified compound screening strategies: a critical evaluation of error sources in experimental and virtual high-throughput screening. QSAR Comb. Sci. 25(12), 1153-1161 (2006).
38. Dobson CM. Chemical space and biology. Nature 432, 824-828 (2004).
39. Sukumar N, Krein M, Breneman CM. Bioinformatics and cheminformatics: where do the twain meet? Curr. Opin. Drug Discov. Devel. 11, 311-319 (2008).
40. Morris RJ, Najmanovich RJ, Kahraman A, Thornton JM. Real spherical harmonic expansion coefficients as 3D shape descriptors for protein binding pocket and ligand comparisons. Bioinformatics 21, 2347-2355 (2005).
41. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat. Chem. Biol. 4, 682-690 (2008).